EA201691765A1 - Молекулы антител против lag-3 и их применения - Google Patents

Молекулы антител против lag-3 и их применения

Info

Publication number
EA201691765A1
EA201691765A1 EA201691765A EA201691765A EA201691765A1 EA 201691765 A1 EA201691765 A1 EA 201691765A1 EA 201691765 A EA201691765 A EA 201691765A EA 201691765 A EA201691765 A EA 201691765A EA 201691765 A1 EA201691765 A1 EA 201691765A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody molecules
applications
molecules against
lag
against lag
Prior art date
Application number
EA201691765A
Other languages
English (en)
Russian (ru)
Inventor
Фредерик Триебель
Кристелль Бриньон
Вальтер А. Блэттлер
Дженнифер Мари Метареза
Кэтрин Энн Сабатос-Пейтон
Хваи Вен Чанг
Герхард Йоханн Фрэй
Original Assignee
Новартис Аг
Иммутеп С.А.С.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52780053&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201691765(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг, Иммутеп С.А.С. filed Critical Новартис Аг
Publication of EA201691765A1 publication Critical patent/EA201691765A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201691765A 2014-03-14 2015-03-13 Молекулы антител против lag-3 и их применения EA201691765A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461953536P 2014-03-14 2014-03-14
US201462059690P 2014-10-03 2014-10-03
US201462094889P 2014-12-19 2014-12-19
PCT/US2015/020474 WO2015138920A1 (en) 2014-03-14 2015-03-13 Antibody molecules to lag-3 and uses thereof

Publications (1)

Publication Number Publication Date
EA201691765A1 true EA201691765A1 (ru) 2016-12-30

Family

ID=52780053

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691765A EA201691765A1 (ru) 2014-03-14 2015-03-13 Молекулы антител против lag-3 и их применения

Country Status (36)

Country Link
US (5) US20150259420A1 (OSRAM)
EP (2) EP3660050A1 (OSRAM)
JP (4) JP6576962B2 (OSRAM)
KR (3) KR102442436B1 (OSRAM)
CN (2) CN106103484B (OSRAM)
AU (3) AU2015229103C9 (OSRAM)
BR (1) BR122024001145A2 (OSRAM)
CA (1) CA2936962C (OSRAM)
CL (2) CL2016002112A1 (OSRAM)
CR (1) CR20160425A (OSRAM)
CU (1) CU24481B1 (OSRAM)
CY (1) CY1122510T1 (OSRAM)
DK (1) DK3116909T3 (OSRAM)
EA (1) EA201691765A1 (OSRAM)
EC (1) ECSP16081503A (OSRAM)
ES (1) ES2770684T3 (OSRAM)
GT (1) GT201600185A (OSRAM)
HR (1) HRP20192346T1 (OSRAM)
HU (1) HUE048531T2 (OSRAM)
IL (3) IL246781B (OSRAM)
JO (1) JOP20150048B1 (OSRAM)
LT (1) LT3116909T (OSRAM)
ME (1) ME03558B (OSRAM)
MX (2) MX389741B (OSRAM)
MY (1) MY187246A (OSRAM)
PE (1) PE20170071A1 (OSRAM)
PH (1) PH12016501545B1 (OSRAM)
PL (1) PL3116909T3 (OSRAM)
PT (1) PT3116909T (OSRAM)
RS (1) RS59853B1 (OSRAM)
SG (1) SG11201605951YA (OSRAM)
SI (1) SI3116909T1 (OSRAM)
TW (4) TWI697500B (OSRAM)
UY (1) UY36032A (OSRAM)
WO (1) WO2015138920A1 (OSRAM)
ZA (1) ZA201604740B (OSRAM)

Families Citing this family (265)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3409278B8 (en) 2011-07-21 2020-11-04 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
PL3081576T3 (pl) 2013-12-12 2020-03-31 Shanghai Hengrui Pharmaceutical Co., Ltd. Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
EP3660050A1 (en) 2014-03-14 2020-06-03 Novartis AG Antibody molecules to lag-3 and uses thereof
WO2015153912A1 (en) 2014-04-03 2015-10-08 Igm Biosciences, Inc. Modified j-chain
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
US20170209574A1 (en) * 2014-10-03 2017-07-27 Novartis Ag Combination therapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
WO2016090034A2 (en) 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
EP3237450B1 (en) * 2014-12-22 2021-03-03 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
KR20240135877A (ko) 2015-03-04 2024-09-12 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄ20 결합 분자 및 그의 용도
JO3746B1 (ar) 2015-03-10 2021-01-31 Aduro Biotech Inc تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
ES2883249T3 (es) * 2015-03-17 2021-12-07 Mayo Found Medical Education & Res Métodos y materiales para evaluar y tratar el cáncer
IL283006B2 (en) 2015-04-01 2023-10-01 Anaptysbio Inc Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
EP3283619B1 (en) 2015-04-17 2023-04-05 Novartis AG Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP4086264B1 (en) 2015-05-18 2023-10-25 Sumitomo Pharma Oncology, Inc. Alvocidib prodrugs having increased bioavailability
SI3303394T1 (sl) 2015-05-29 2020-10-30 Agenus Inc. Protitelesa proti-CTLA-4 in postopki njihove uporabe
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
PL3317301T3 (pl) 2015-07-29 2021-11-15 Novartis Ag Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
SG10202010506TA (en) 2015-07-30 2020-11-27 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
IL257798B2 (en) * 2015-09-02 2024-10-01 Immutep Sas Antibodies against LAG-3
US11747346B2 (en) 2015-09-03 2023-09-05 Novartis Ag Biomarkers predictive of cytokine release syndrome
HK1252791A1 (zh) 2015-09-30 2019-06-06 Igm Biosciences, Inc. 具有经修饰的j链的结合分子
DK3356401T3 (da) * 2015-09-30 2020-09-07 Igm Biosciences Inc Bindingsmolekyler med modificeret j-kæde
CN114773481B (zh) 2015-10-02 2025-04-29 豪夫迈·罗氏有限公司 对pd1和tim3特异性的双特异性抗体
TWI756187B (zh) * 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
EP3973988A1 (en) * 2015-11-04 2022-03-30 Duke University Combination therapy of immunotoxin and checkpoint inhibitor
KR102220275B1 (ko) * 2015-11-18 2021-02-26 머크 샤프 앤드 돔 코포레이션 Pd1 및/또는 lag3 결합제
WO2017087901A2 (en) * 2015-11-19 2017-05-26 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
US10954301B2 (en) 2015-12-14 2021-03-23 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
EP3399989B1 (en) 2015-12-16 2023-08-09 Merck Sharp & Dohme LLC Anti-lag3 antibodies and antigen-binding fragments
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
US11413340B2 (en) 2015-12-22 2022-08-16 Novartis Ag Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
EP3402508A4 (en) * 2016-01-11 2019-09-25 Flagship Pioneering Innovations V, Inc. METHOD AND COMPOSITIONS FOR MODULATING THE THYMUS FUNCTION
WO2017122130A1 (en) 2016-01-11 2017-07-20 Novartis Ag Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
IL261188B (en) 2016-03-04 2022-08-01 Jn Biosciences Llc An anti-tigit antibody that binds to the tigit polypeptide on one or more amino acid residues
AU2017225733A1 (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
EP3225253A1 (en) 2016-04-01 2017-10-04 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
MX393609B (es) * 2016-05-18 2025-03-24 Boehringer Ingelheim Int Anticuerpos anti pd-1 y anti-lag3 para el tratamiento de cancer
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
SG11201811184UA (en) 2016-06-20 2019-01-30 F Star Beta Ltd Lag -3 binding members
BR112018076519A8 (pt) * 2016-06-20 2022-07-12 F Star Delta Ltd Moléculas de ligação que se ligam a pd-l1 e lag-3
ES2915410T3 (es) 2016-06-23 2022-06-22 Jiangsu Hengrui Medicine Co Anticuerpo contra LAG-3, fragmento de unión a antígeno del mismo y aplicación farmacéutica del mismo
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
EA039718B1 (ru) * 2016-07-21 2022-03-03 Регенерон Фармасьютикалз, Инк. Антитела к lag3 и их применения
US20180043011A1 (en) * 2016-08-10 2018-02-15 Wisconsin Alumni Research Foundation PI3-Kinase Inhibition and LAG-3 Checkpoint blockade as a Combination Therapy for Cancer
WO2018047894A1 (ja) 2016-09-08 2018-03-15 第一三共株式会社 自己免疫疾患治療用抗体
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
KR102576042B1 (ko) 2016-10-11 2023-09-07 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
BR112019006876A2 (pt) * 2016-10-13 2019-06-25 Symphogen As anticorpos e composições anti-lag-3
US11155624B2 (en) 2016-11-01 2021-10-26 Anaptysbio, Inc. Antibodies directed against programmed death-1 (PD-1)
EP3689419A1 (en) 2016-11-01 2020-08-05 AnaptysBio, Inc. Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
WO2018083087A2 (en) 2016-11-02 2018-05-11 Glaxosmithkline Intellectual Property (No.2) Limited Binding proteins
ES3008937T3 (en) 2016-11-04 2025-03-25 Aximmune Inc Beta-alethine in combination with immune modulators and uses thereof
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
JP2019536460A (ja) 2016-12-03 2019-12-19 ジュノー セラピューティクス インコーポレイテッド Ｃａｒ−ｔ細胞の調節方法
IL266918B2 (en) 2016-12-07 2024-03-01 Agenus Inc Anti-ctla-4 antibodies and methods of use thereof
SG10201913083SA (en) 2017-01-09 2020-03-30 Tesaro Inc Methods of treating cancer with anti-tim-3 antibodies
CN110382545A (zh) 2017-01-09 2019-10-25 泰萨罗公司 用抗pd-1抗体治疗癌症的方法
CN110650974B (zh) 2017-02-10 2024-04-19 瑞泽恩制药公司 用于免疫-pet成像的放射性标记的抗-lag3抗体
AU2018226298B2 (en) 2017-02-22 2022-02-17 I-Mab Biopharma (Hangzhou) Co., Ltd. Anti-LAG-3 antibodies and uses thereof
JOP20190218A1 (ar) 2017-03-22 2019-09-22 Boehringer Ingelheim Int مركبات ثنائية النيوكليوتيدات حلقية معدلة
RU2761377C2 (ru) 2017-04-03 2021-12-07 Ф. Хоффманн-Ля Рош Аг Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15
JP2020513009A (ja) 2017-04-05 2020-04-30 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ Ｐｄ−１、ｔｉｍ−３、およびｌａｇ−３を標的とする併用治療
EP3606556A1 (en) 2017-04-05 2020-02-12 Boehringer Ingelheim International GmbH Anticancer combination therapy
FI3606955T3 (fi) 2017-04-05 2025-01-08 Hoffmann La Roche Pd1:een ja lag3:een spesifisesti sitoutuvia bispesifisiä vasta-aineita
BR112019018779A2 (pt) * 2017-04-05 2020-05-05 Hoffmann La Roche anticorpos isolados, ácido nucleico isolado, célula hospedeira, método para tratar um indivíduo tendo câncer e para produzir um anticorpo, formulação farmacêutica e uso do anticorpo
KR102769634B1 (ko) 2017-04-27 2025-02-19 테사로, 인코포레이티드 림프구 활성화 유전자-3 (lag-3)에 대한 항체 작용제 및 그의 용도
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
AU2018277824A1 (en) 2017-05-30 2019-10-17 Bristol-Myers Squibb Company Treatment of LAG-3 positive tumors
MX2019012076A (es) 2017-05-30 2019-12-09 Bristol Myers Squibb Co Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1).
EP3630842A2 (en) * 2017-05-30 2020-04-08 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
WO2018223002A1 (en) 2017-06-01 2018-12-06 Xencor, Inc. Bispecific antibodies that bind cd 123 cd3
WO2018223004A1 (en) 2017-06-01 2018-12-06 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3
CN111225675B (zh) 2017-06-02 2024-05-03 朱诺治疗学股份有限公司 使用过继细胞疗法治疗的制品和方法
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
KR20200021087A (ko) 2017-06-22 2020-02-27 노파르티스 아게 Cd73에 대한 항체 분자 및 이의 용도
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
WO2018234879A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
JP2020525483A (ja) 2017-06-27 2020-08-27 ノバルティス アーゲー 抗ｔｉｍ−３抗体のための投与レジメンおよびその使用
EP3644721A1 (en) 2017-06-29 2020-05-06 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
TWI875679B (zh) * 2017-07-06 2025-03-11 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的抗體
CN111163798A (zh) * 2017-07-20 2020-05-15 诺华股份有限公司 用于抗lag-3抗体的给药方案及其用途
TWI785098B (zh) 2017-08-18 2022-12-01 開曼群島商科賽睿生命科學公司 Tg02之多晶型
KR20200042937A (ko) 2017-08-30 2020-04-24 페인스 테라퓨틱스 인코포레이티드 항-lag-3 항체 및 이의 용도
CN111148514A (zh) 2017-08-31 2020-05-12 Io治疗公司 与免疫调节剂联合应用于癌症免疫治疗的rar选择性激动剂
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
TW201927336A (zh) 2017-10-05 2019-07-16 日商第一三共股份有限公司 細胞毒性ｔ細胞耗竭用組成物
EP3700933A1 (en) 2017-10-25 2020-09-02 Novartis AG Antibodies targeting cd32b and methods of use thereof
WO2019089755A1 (en) * 2017-10-31 2019-05-09 Western Oncolytics Ltd. Platform oncolytic vector for systemic delivery
WO2019089969A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
WO2019090003A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
WO2019094637A1 (en) * 2017-11-08 2019-05-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
RU2020119578A (ru) 2017-11-16 2021-12-17 Новартис Аг Комбинированные терапии
MA51228A (fr) * 2017-11-29 2020-10-07 Taiho Pharmaceutical Co Ltd Agent antitumoral
MX2020005478A (es) 2017-11-29 2020-08-27 Taiho Pharmaceutical Co Ltd Compuestos de sulfonamida y usos de los mismos.
SG11202005005YA (en) 2017-11-30 2020-06-29 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
JP2021506260A (ja) 2017-12-15 2021-02-22 ジュノー セラピューティクス インコーポレイテッド 抗ｃｃｔ５結合分子およびその使用方法
WO2019121906A1 (en) 2017-12-19 2019-06-27 F-Star Beta Limited Specific pd-l1 binding sequences inserted in a ch3 domain
AU2018391217A1 (en) 2017-12-22 2020-07-09 Jiangsu Hengrui Medicine Co., Ltd. LAG-3 antibody pharmaceutical composition and use thereof
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
WO2019129136A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
WO2019129137A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
CN109970857B (zh) 2017-12-27 2022-09-30 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
EP3737408A1 (en) 2018-01-08 2020-11-18 Novartis AG Immune-enhancing rnas for combination with chimeric antigen receptor therapy
AU2019215031B2 (en) 2018-01-31 2025-10-09 Novartis Ag Combination therapy using a chimeric antigen receptor
EP3746117A1 (en) 2018-01-31 2020-12-09 Celgene Corporation Combination therapy using adoptive cell therapy and checkpoint inhibitor
US20200354457A1 (en) 2018-01-31 2020-11-12 Hoffmann-La Roche Inc. Bispecific antibodies comprising an antigen-binding site binding to lag3
EP3746119A4 (en) * 2018-02-01 2021-11-10 Merck Sharp & Dohme Corp. METHOD OF TREATMENT FOR CANCER OR INFECTION USING A COMBINATION OF ANTI-PD-1 ANTIBODY, ANTI-LAG3 ANTIBODY, AND ANTI-TIGITE ANTIBODY
US20200399383A1 (en) 2018-02-13 2020-12-24 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
WO2019165982A1 (en) 2018-02-28 2019-09-06 WuXi Biologics Ireland Limited Monoclonal antibody against human lag-3, method for preparing same, and use thereof
CN110305215B (zh) * 2018-03-20 2023-11-03 基石药业 新型抗lag-3抗体多肽
EP3768720A4 (en) * 2018-03-20 2022-01-05 Wuxi Biologics Ireland Limited NEW ANTI-BODY ANTI-LAG-3 POLYPEPTIDE
EP3774834A1 (en) 2018-03-27 2021-02-17 Boehringer Ingelheim International GmbH Cyclic dinucleotide compounds containing 2-aza-hypoxanthine or 6h-pytazolo[1,5-d][1,2,4]triazin-7-one as sting agonists
WO2019185476A1 (en) 2018-03-27 2019-10-03 Boehringer Ingelheim International Gmbh Modified cyclic dinucleotide compounds
US11958903B2 (en) 2018-03-30 2024-04-16 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against LAG-3 and uses thereof
JP7104458B2 (ja) * 2018-04-02 2022-07-21 上海博威生物医薬有限公司 リンパ球活性化遺伝子－３（ｌａｇ－３）結合抗体およびその使用
CN110343178B (zh) * 2018-04-03 2022-07-22 上海开拓者生物医药有限公司 抗人lag-3单克隆抗体及其应用
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
JP2021521784A (ja) 2018-04-18 2021-08-30 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５ＲａＦｃ融合タンパク質とＰＤ−１抗原結合ドメインを含むＰＤ−１標的化ヘテロダイマー融合タンパク質およびそれらの使用
IL310398A (en) 2018-04-18 2024-03-01 Xencor Inc Proteins from heterodimeric il-15/il-15rα fc and their uses
MX2020011588A (es) 2018-05-03 2020-12-07 Shanghai Epimab Biotherapeutics Co Ltd Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas.
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
US20210205449A1 (en) 2018-06-01 2021-07-08 Novartis Ag Dosing of a bispecific antibody that bind cd123 and cd3
JP7398396B2 (ja) 2018-06-01 2023-12-14 ノバルティス アーゲー Ｂｃｍａに対する結合分子及びその使用
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CN110606892B (zh) * 2018-06-14 2023-09-26 华博生物医药技术（上海）有限公司 一种高亲和力高生物活性的lag-3抗体及其应用
JP7003295B2 (ja) * 2018-06-29 2022-01-20 ワイ－バイオロジクス・インコーポレイテッド Ｌａｇ－３に特異的に結合する単クローン抗体及びその用途
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
PL3820573T3 (pl) 2018-07-10 2024-02-19 Novartis Ag Pochodne 3-(5-hydroksy-1-oksoizoindolin-2-ylo)piperydyno-2,6-dionu i ich zastosowanie w leczeniu chorób zależnych od palca cynkowego z rodziny ikaros 2 (ikzf2)
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
AU2019301204B2 (en) 2018-07-12 2025-10-23 Invox Pharma Limited Antibody molecules that bind PD-L1 and CD137
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
MX2021000399A (es) 2018-07-12 2021-05-27 F Star Therapeutics Ltd Moleculas de anticuerpo que se unen a cd137 y ox40.
BR112021000964A2 (pt) 2018-07-25 2021-04-20 Novartis Ag inibidores do inflamassoma de nlrp3
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
TWI852940B (zh) 2018-09-04 2024-08-21 美商泰沙羅公司 治療癌症之方法
US11638730B2 (en) 2018-09-26 2023-05-02 Astellas Pharma Inc. Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
WO2020069405A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
WO2020069409A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
CN110960679A (zh) * 2018-09-28 2020-04-07 江苏康缘药业股份有限公司 一种抗肿瘤的药物组合物及其应用
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
CA3116188A1 (en) 2018-10-12 2020-04-16 Xencor, Inc. Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
US20230053449A1 (en) 2018-10-31 2023-02-23 Novartis Ag Dc-sign antibody drug conjugates
KR20210113169A (ko) 2018-11-01 2021-09-15 주노 쎄러퓨티크스 인코퍼레이티드 Β세포 성숙 항원에 특이적인 키메라 항원 수용체를 이용한 치료 방법
MA54079A (fr) 2018-11-01 2021-09-08 Juno Therapeutics Inc Récepteurs antigéniques chimériques spécifiques du gprc5d (élément d du groupe 5 de classe c des récepteurs couplés à la protéine g)
CN113271963A (zh) 2018-11-16 2021-08-17 朱诺治疗学股份有限公司 给予工程化t细胞以治疗b细胞恶性肿瘤的方法
BR112021010354A2 (pt) 2018-11-30 2021-11-03 Juno Therapeutics Inc Métodos para o tratamento usando terapia celular adotiva
CA3119807A1 (en) 2018-12-04 2020-06-11 Sumitomo Dainippon Pharma Oncology, Inc. Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
CN113271945A (zh) 2018-12-20 2021-08-17 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
US11618776B2 (en) 2018-12-20 2023-04-04 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
US20220025036A1 (en) 2018-12-21 2022-01-27 Novartis Ag Use of il-1beta binding antibodies
JP7607564B2 (ja) 2018-12-21 2024-12-27 ノバルティス アーゲー Ｐｍｅｌ１７に対する抗体及びその結合体
KR20210108422A (ko) 2018-12-21 2021-09-02 노파르티스 아게 IL-1β 결합 항체의 용도
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
CN113227137A (zh) 2018-12-21 2021-08-06 诺华股份有限公司 IL-1β抗体在骨髓增生异常综合征的治疗或预防中的用途
TWI756621B (zh) * 2019-01-25 2022-03-01 大陸商信達生物製藥（蘇州）有限公司 新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體
CA3123303A1 (en) 2019-01-29 2020-08-06 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
CA3127502A1 (en) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
EP3924055B1 (en) 2019-02-15 2024-04-03 Novartis AG Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP7483732B2 (ja) 2019-02-15 2024-05-15 ノバルティス アーゲー ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
CA3133460A1 (en) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
AU2020248002A1 (en) 2019-03-26 2021-10-21 The Regents Of The University Of Michigan Small molecule degraders of STAT3
EP3947403A1 (en) 2019-03-29 2022-02-09 The Regents Of The University Of Michigan Stat3 protein degraders
JP2022530496A (ja) * 2019-04-26 2022-06-29 ウーシー バイオロジクス アイルランド リミテッド Ｐｄ－１およびｌａｇ－３に対する二重特異性抗体
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
WO2020241749A1 (ja) * 2019-05-29 2020-12-03 大鵬薬品工業株式会社 スルホンアミド化合物と免疫調節剤を用いるがん併用療法
CN112010972B (zh) * 2019-05-31 2023-01-10 瑞阳(苏州)生物科技有限公司 与人lag-3蛋白结合的抗体及其编码基因和应用
US20220220204A1 (en) * 2019-06-12 2022-07-14 Nanjing GenScript Biotech Co., Ltd. Anti-pd-l1/anti-lag-3 multiple antigen binding proteins and methods of use thereof
EP3983084A1 (en) 2019-06-12 2022-04-20 Vanderbilt University Amino acid transport inhibitors and the uses thereof
AU2020291936A1 (en) 2019-06-12 2022-02-03 Vanderbilt University Dibenzylamines as amino acid transport inhibitors
AU2020303586A1 (en) * 2019-06-26 2022-01-20 Amunix Pharmaceuticals, Inc. EGFR antigen binding fragments and compositions comprising same
BR112021026334A2 (pt) 2019-06-27 2022-05-10 Medstar Health Macrófagos ativados por hdac6, composições, e usos dos mesmos
WO2021003417A1 (en) 2019-07-03 2021-01-07 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
CN114340680A (zh) 2019-07-05 2022-04-12 坦博公司 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途
JP7738909B2 (ja) 2019-07-16 2025-09-16 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン Ｅｅｄ阻害剤としてのイミダゾピリミジンおよびその使用
CN114641337A (zh) 2019-08-27 2022-06-17 密歇根大学董事会 Cereblon e3连接酶抑制剂
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
US20220380368A1 (en) 2019-09-19 2022-12-01 The Regents Of The University Of Michigan Spirocyclic androgen receptor protein degraders
KR20220103095A (ko) * 2019-09-26 2022-07-21 우시 바이올로직스 아일랜드 리미티드 신규 항-pd-l1/항-lag-3 이중특이적 항체 및 그의 용도
CN115916233A (zh) 2019-10-03 2023-04-04 Xencor股份有限公司 靶向IL-12异源二聚体Fc融合蛋白
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
MX2022004766A (es) 2019-10-21 2022-05-16 Novartis Ag Terapias combinadas con venetoclax e inhibidores de tim-3.
TW202128191A (zh) 2019-10-21 2021-08-01 瑞士商諾華公司 Tim-3抑制劑及其用途
KR20220093349A (ko) 2019-11-08 2022-07-05 브리스톨-마이어스 스큅 컴퍼니 흑색종에 대한 lag-3 길항제 요법
TW202135859A (zh) 2019-12-20 2021-10-01 瑞士商諾華公司 組合療法
BR112022012310A2 (pt) 2020-01-17 2022-09-06 Novartis Ag Combinação compreendendo um inibidor de tim-3 e um agente hipometilante para uso no tratamento de síndrome mielodisplásica ou leucemia mielomonocítica crônica
WO2021171264A1 (en) 2020-02-28 2021-09-02 Novartis Ag Dosing of a bispecific antibody that binds cd123 and cd3
US20230159573A1 (en) 2020-03-26 2023-05-25 The Regents Of The University Of Michigan Small molecule stat protein degraders
AU2021251265A1 (en) 2020-04-10 2022-11-03 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting B-cell maturation antigen
AR122493A1 (es) 2020-06-02 2022-09-14 Arcus Biosciences Inc Anticuerpos anti-tigit
CN114605544B (zh) * 2020-06-05 2023-08-01 北京天广实生物技术股份有限公司 Lag3抗体及其用途
MX2022016544A (es) 2020-06-22 2023-04-05 Ngm Biopharmaceuticals Inc Agentes de union a lair-1 y metodos para su uso.
KR20230027056A (ko) 2020-06-23 2023-02-27 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
US20230257365A1 (en) 2020-07-10 2023-08-17 The Regents Of The University Of Michigan Small molecule androgen receptor protein degraders
WO2022011205A1 (en) 2020-07-10 2022-01-13 The Regents Of The University Of Michigan Androgen receptor protein degraders
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP4192506A1 (en) 2020-08-07 2023-06-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
KR20230050389A (ko) 2020-08-13 2023-04-14 브리스톨-마이어스 스큅 컴퍼니 Il-2를 관심 표적 세포로 재지시하는 방법
MX2023002332A (es) 2020-08-28 2023-03-21 Bristol Myers Squibb Co Terapia con antagonistas del gen 3 de activacion de linfocitos (lag-3) para carcinoma hepatocelular.
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022072820A1 (en) 2020-10-02 2022-04-07 Dracen Pharmaceuticals, Inc. Lyophilized composition comprising (s)-isopropyl 2-((s)-2- acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5- oxohexanoate for subcutaneous administration and the use thereof
CA3196496A1 (en) 2020-10-23 2022-04-28 Laurence David TOMS Lag-3 antagonist therapy for lung cancer
IL302569A (en) 2020-11-06 2023-07-01 Novartis Ag Cd19 binding molecules and uses thereof
CN114621345B (zh) * 2020-12-10 2022-11-29 北京东方百泰生物科技股份有限公司 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
CA3196999A1 (en) 2020-12-28 2022-07-07 Masano HUANG Methods of treating tumors
SMT202500208T1 (it) 2020-12-28 2025-07-22 Bristol Myers Squibb Co Composizioni anticorpali e metodi per il loro uso
CA3210196A1 (en) 2021-01-29 2022-08-04 Board Of Regents, The University Of Texas System Methods of treating cancer with kinase inhibitors
CA3209479A1 (en) 2021-02-03 2022-08-11 Mozart Therapeutics, Inc. Binding agents and methods of using the same
US20240190874A1 (en) 2021-03-03 2024-06-13 The Regents Of The University Of Michigan Small molecule degraders of androgen receptor
US20240166647A1 (en) 2021-03-03 2024-05-23 The Regents Of The University Of Michigan Cereblon Ligands
JP2024514245A (ja) 2021-03-29 2024-03-29 ジュノー セラピューティクス インコーポレイテッド チェックポイント阻害剤療法とｃａｒ ｔ細胞療法との組合せを用いた投薬および処置のための方法
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AU2022253474A1 (en) 2021-04-08 2023-11-16 Board Of Regents, The University Of Texas System Compounds and methods for theranostic targeting of parp activity
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations
KR20230170738A (ko) 2021-04-16 2023-12-19 노파르티스 아게 항체 약물 접합체 및 이의 제조 방법
US20220347282A1 (en) * 2021-04-28 2022-11-03 Wisconsin Alumni Research Foundation Anti-tumor dna vaccine with pd-1 and lag-3 pathway blockade
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
CN115403670A (zh) 2021-05-26 2022-11-29 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途
CN115611983A (zh) 2021-07-14 2023-01-17 三优生物医药(上海)有限公司 Cldn18.2结合分子及其用途
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
CN118176214A (zh) 2021-10-29 2024-06-11 百时美施贵宝公司 血液癌症的lag-3拮抗剂疗法
US20250313625A1 (en) * 2021-11-01 2025-10-09 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-lag3 antibodies
MX2024008831A (es) 2022-01-26 2024-07-25 Bristol Myers Squibb Co Terapia combinada para carcinoma hepatocelular.
WO2023164638A1 (en) 2022-02-25 2023-08-31 Bristol-Myers Squibb Company Combination therapy for colorectal carcinoma
JP2023140319A (ja) 2022-03-22 2023-10-04 アッヴィ・インコーポレイテッド ブルトン型チロシンキナーゼを分解するためのピリミジン
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
EP4543923A1 (en) 2022-06-22 2025-04-30 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
US20240041929A1 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
AR131320A1 (es) 2022-12-13 2025-03-05 Juno Therapeutics Inc Receptores de antígenos quiméricos específicos para baff-r y cd19 y métodos y usos de los mismos
WO2024137776A1 (en) 2022-12-21 2024-06-27 Bristol-Myers Squibb Company Combination therapy for lung cancer
WO2024163477A1 (en) 2023-01-31 2024-08-08 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
KR20250001490A (ko) * 2023-06-28 2025-01-07 주식회사 니오바이오파마슈티컬스 항-lag-3 항체, 항원 결합성 단편 및 이들의 용도
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
WO2025151487A2 (en) 2024-01-08 2025-07-17 Regents Of The University Of Michigan Small-molecule inhibitors of adar1
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
US20250269052A1 (en) 2024-02-27 2025-08-28 Bristol-Myers Squibb Company Anti-ceacam5 antibody drug conjugates
WO2025245489A1 (en) 2024-05-24 2025-11-27 Bristol-Myers Squibb Company Treatment of tumors in subjects having fgl-1 positive samples

Family Cites Families (527)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4433059A (en) 1981-09-08 1984-02-21 Ortho Diagnostic Systems Inc. Double antibody conjugate
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
DE3381783D1 (de) 1982-03-03 1990-09-13 Genentech Inc Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4978672A (en) 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
DE3884470T2 (de) 1987-06-17 1994-03-10 Sandoz Ag Cyclosporine und deren Benutzung als Arzneimittel.
JPH021556A (ja) 1988-06-09 1990-01-05 Snow Brand Milk Prod Co Ltd ハイブリッド抗体及びその作製方法
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FR2636953B1 (fr) 1988-09-26 1990-12-14 Roussy Inst Gustave Nouveaux polypeptides produits par des lymphocytes humains, genes codant pour ces polypeptides et applications pharmaceutiques et biologiques
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
AU6290090A (en) 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
FR2656800B1 (fr) 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5976877A (en) 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5273743A (en) 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9012995D0 (en) 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU664976B2 (en) 1990-08-29 1995-12-14 Gene Pharming Europe Bv Homologous recombination in mammalian cells
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
US6596536B1 (en) 1991-02-08 2003-07-22 Aventis Pharma S.A. Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
EP0529033B1 (fr) 1991-02-08 2006-08-30 Aventis Pharma S.A. Sequences nucleotidiques codant pour des regions variables de chaines alpha des recepteurs des lymphocytes humains ainsi que leurs applications
CA2079881C (fr) 1991-02-12 2007-11-06 Thierry Hercend Sequences nucleotidiques codant pour des regions variables de chaines .beta. des recepteurs des lymphocytes t humains, segments peptidiques correspondants et les applications diagnostiques et therapeutiques
ES2287206T3 (es) 1991-03-01 2007-12-16 Dyax Corporation Proceso para el desarrollo de mini-proteinas de union.
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US6511663B1 (en) 1991-06-11 2003-01-28 Celltech R&D Limited Tri- and tetra-valent monospecific antigen-binding proteins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
KR100238712B1 (ko) 1991-06-27 2000-01-15 스티븐 비. 데이비스 씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
EP0654085B1 (en) 1992-01-23 1997-04-02 MERCK PATENT GmbH Monomeric and dimeric antibody-fragment fusion proteins
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
AU675223B2 (en) 1992-05-08 1997-01-30 Creative Biomolecules, Inc. Chimeric multivalent protein analogues and methods of use thereof
US5260074A (en) 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DE69330523D1 (de) 1992-08-21 2001-09-06 Vrije Universiteit Brussel Bru Immunoglobuline ohne leichte ketten
EP0672068A4 (en) 1992-09-25 1997-02-26 Commw Scient Ind Res Org TARGET MOLECULES BINDING POLYPEPTIDES.
GB9221657D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
ATE348110T1 (de) 1992-10-28 2007-01-15 Genentech Inc Hvegf rezeptor als vegf antagonist
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
GB9323648D0 (en) 1992-11-23 1994-01-05 Zeneca Ltd Proteins
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
US5635602A (en) 1993-08-13 1997-06-03 The Regents Of The University Of California Design and synthesis of bispecific DNA-antibody conjugates
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
IL108501A (en) 1994-01-31 1998-10-30 Mor Research Applic Ltd Antibodies and pharmaceutical compositions containing them
JPH07291996A (ja) 1994-03-01 1995-11-07 Yuu Honshiyo ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物
RU2178306C2 (ru) 1994-05-06 2002-01-20 Энститю Гюстав Русси Растворимые полипептидные фракции протеина lag-3, способ получения, терапевтическая композиция, антитело
EP0787185A2 (en) 1994-10-20 1997-08-06 MorphoSys AG Targeted hetero-association of recombinant proteins to multi-functional complexes
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
DE69633175T2 (de) 1995-05-23 2005-08-11 Morphosys Ag Multimere proteine
JP2000508226A (ja) 1995-07-21 2000-07-04 アプライド リサーチ システムズ アース ホールディング エヌ．ヴィ． Ｌａｇ−３タンパク質によるｔｈ１リンパ球を検出、同定、単離並びに選択的に標識およびターゲッティングする方法
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
DE69730209T2 (de) 1996-04-04 2005-04-14 Unilever N.V. Multivalentes und multispezifisches Antigenbindungsprotein
TW533205B (en) 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
JP4440344B2 (ja) 1996-08-16 2010-03-24 シェーリング コーポレイション 哺乳動物細胞表面抗原；関連試薬
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
JP2000516101A (ja) 1996-11-28 2000-12-05 アンスティテュ ギュスタブ ルシ Ｌａｇ−３タンパク質の変異体、その発現及び使用
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
WO1998045331A2 (en) 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
SI1695985T1 (sl) 1997-04-07 2011-06-30 Genentech Inc Postopki za tvorbo humaniziranih protiteles z naključno mutagenezo
WO1998049198A1 (en) 1997-04-30 1998-11-05 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US20030207346A1 (en) 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
ES2231991T3 (es) 1997-06-11 2005-05-16 Borean Pharma A/S Modulo de trimerizacion.
EP0900841A1 (en) 1997-06-18 1999-03-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) LAG-3 splice variants
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
EP0893507A1 (en) 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
US6509173B1 (en) 1997-10-21 2003-01-21 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
BR9813276A (pt) 1997-10-27 2000-08-22 Unilever Nv Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma
ATE283364T1 (de) 1998-01-23 2004-12-15 Vlaams Interuniv Inst Biotech Mehrzweck-antikörperderivate
CA2319236A1 (en) 1998-02-09 1999-08-12 Genentech, Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
CZ121599A3 (cs) 1998-04-09 1999-10-13 Aventis Pharma Deutschland Gmbh Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
EP1073465B1 (en) 1998-04-15 2005-06-22 The Brigham And Women's Hospital, Inc. T cell inhibitory receptor compositions and uses thereof
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
DK1100830T3 (da) 1998-07-28 2004-01-19 Micromet Ag Heterominiantistoffer
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
US7041474B2 (en) 1998-12-30 2006-05-09 Millennium Pharmaceuticals, Inc. Nucleic acid encoding human tango 509
IL129299A0 (en) 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
FR2794025A1 (fr) 1999-05-25 2000-12-01 Transgene Sa Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere
WO2000073498A1 (en) 1999-06-02 2000-12-07 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
WO2001003720A2 (en) 1999-07-12 2001-01-18 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
IL148021A0 (en) 1999-08-23 2002-09-12 Dana Farber Cancer Inst Inc Novel b7-4 molecules and uses therefor
DK1210428T3 (en) 1999-08-23 2015-06-15 Dana Farber Cancer Inst Inc PD-1, a receptor for B7-4 AND USE THEREOF
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
PT1234031T (pt) 1999-11-30 2017-06-26 Mayo Foundation B7-h1, uma nova molécula imunoregulatória
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
WO2001090192A2 (en) 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
JP2004500863A (ja) 2000-06-06 2004-01-15 ブリストル−マイヤーズ　スクイブ　カンパニー 免疫調節に有用なｂ７関連核酸およびポリペプチド
MXPA02012434A (es) 2000-06-16 2004-09-06 Cambridge Antibody Tech Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii.
US20020164600A1 (en) 2000-06-28 2002-11-07 Gordon Freeman PD-L2 molecules: novel PD-1 ligands and uses therefor
EP1294904A1 (en) 2000-06-30 2003-03-26 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Heterodimeric fusion proteins
WO2002008293A2 (en) 2000-07-25 2002-01-31 Immunomedics Inc. Multivalent target binding protein
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
MXPA03002413A (es) 2000-09-20 2003-06-19 Amgen Inc Moleculas tipo b7 y uso de las mismas.
US7132109B1 (en) 2000-10-20 2006-11-07 University Of Connecticut Health Center Using heat shock proteins to increase immune response
KR100870123B1 (ko) 2000-10-20 2008-11-25 츄가이 세이야꾸 가부시키가이샤 저분자화 아고니스트 항체
EP1334659B1 (en) 2000-11-15 2012-01-11 Ono Pharmaceutical Co., Ltd. Pd-1-lacking mouse and use thereof
JP2002194491A (ja) 2000-12-27 2002-07-10 Daido Steel Co Ltd ばね用鋼材
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2002302919A1 (en) 2001-02-22 2002-10-03 Institut Pasteur Comparative mycobacterial geneomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
AU2002247826A1 (en) 2001-03-13 2002-09-24 University College London Specific binding members
EP2388590A1 (en) 2001-04-02 2011-11-23 Dana Farber Cancer Institute PD-1, a receptor for B7-4, and uses thereof
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
US20020146753A1 (en) 2001-04-06 2002-10-10 Henrik Ditzel Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease
AU2002258941A1 (en) 2001-04-20 2002-11-05 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
US6727072B2 (en) 2001-05-01 2004-04-27 Dako Corporation EGF-r detection kit
US6592849B2 (en) 2001-06-21 2003-07-15 Colgate Palmolive Company Chewing gum to control malodorous breath
WO2003002609A2 (en) 2001-06-28 2003-01-09 Domantis Limited Dual-specific ligand and its use
US7553939B2 (en) 2001-06-29 2009-06-30 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes and methods of use thereof
US7838220B2 (en) 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
US8709412B2 (en) 2001-06-29 2014-04-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of TIM receptor activity in combination with cytoreductive therapy
JP2003029846A (ja) 2001-07-11 2003-01-31 Sanyo Electric Co Ltd 流量調整器および流量調整器を備えた飲料供給装置
EP1445264B1 (en) 2001-07-31 2011-09-14 Ono Pharmaceutical Co., Ltd. Substance specific to pd-1
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
DE60124912T2 (de) 2001-09-14 2007-06-14 Affimed Therapeutics Ag Multimerische, einzelkettige, Tandem-Fv-Antikörper
DE60234369D1 (de) 2001-09-19 2009-12-24 Alexion Pharma Inc Manipulierte matrizen und ihre verwendung bei der single-primer-amplifikation
ATE519779T1 (de) 2001-09-19 2011-08-15 Roussy Inst Gustave An das glu-pro motiv-bindende proteine und peptide, diese enthaltende therapeutische zusammensetzungen und deren anwendungen
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
EP1441737B1 (en) 2001-10-30 2006-08-09 Novartis AG Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
WO2003049684A2 (en) 2001-12-07 2003-06-19 Centocor, Inc. Pseudo-antibody constructs
AU2003303082B2 (en) 2002-01-30 2009-07-02 Dana-Farber Cancer Institute, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
KR100956195B1 (ko) 2002-02-01 2010-05-06 어리어드 파마슈티칼스, 인코포레이티드 인 함유 화합물 및 이의 용도
JP2005535290A (ja) 2002-02-22 2005-11-24 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
AU2003209446B2 (en) 2002-03-01 2008-09-25 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
TWI338685B (en) 2002-03-13 2011-03-11 Array Biopharma Inc N3 alkylated benzimid azole derivatives as mek inhibitors
WO2003087163A1 (en) 2002-04-15 2003-10-23 Chugai Seiyaku Kabushiki Kaisha METHOD OF CONSTRUCTING scDb LIBRARY
CA2481507A1 (en) 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
EP1537878B1 (en) 2002-07-03 2010-09-22 Ono Pharmaceutical Co., Ltd. Immunopotentiating compositions
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
ITTO20020602A1 (it) * 2002-07-10 2004-01-12 Infm Istituto Naz Per La Fisi Microscopio ottico atto ad operare una modulazione tridimensionale rapida della posizione del punto di osservazione
US7052694B2 (en) 2002-07-16 2006-05-30 Mayo Foundation For Medical Education And Research Dendritic cell potentiation
US20040047858A1 (en) 2002-09-11 2004-03-11 Blumberg Richard S. Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
AU2003298607B9 (en) 2002-10-29 2011-08-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2505994A1 (en) 2002-11-15 2004-06-03 Chiron Corporation Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
US7449300B2 (en) 2002-11-21 2008-11-11 Mayo Foundation For Medical Education And Research Detection of antibodies specific for B7-H1 in subjects with diseases or pathological conditions mediated by activated T cells
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
EP1591527B1 (en) 2003-01-23 2015-08-26 Ono Pharmaceutical Co., Ltd. Substance specific to human pd-1
MXPA05008335A (es) 2003-02-11 2006-05-04 Vernalis Cambridge Ltd Compuestos de isoxazol como inhibidores de las proteinas de choque por calor.
WO2005035732A2 (en) 2003-02-19 2005-04-21 Dyax Corporation Papp-a ligands
EP1596871A4 (en) 2003-02-28 2006-08-23 Drew M Pardoll T-CELL REGULATION
GB0305702D0 (en) 2003-03-12 2003-04-16 Univ Birmingham Bispecific antibodies
US20050003403A1 (en) 2003-04-22 2005-01-06 Rossi Edmund A. Polyvalent protein complex
MXPA05012475A (es) 2003-05-23 2006-05-25 Wyeth Corp Anticuerpos y moleculas relacionadas con el ligando para el receptor tnf inducido por glucorticoides (gitr) y el ligando (gitr) y usos de los mismos.
RS20050885A (sr) 2003-05-30 2008-04-04 Genentech Lečenje sa anti-vegf antitelima
CA2529945A1 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
EP1638510B1 (en) 2003-07-01 2015-09-02 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US20050048054A1 (en) 2003-07-11 2005-03-03 Shino Hanabuchi Lymphocytes; methods
US7696322B2 (en) 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
CN1902227A (zh) 2003-10-03 2007-01-24 布赖汉姆妇女医院 Tim－3配体及其方法
CA2541360A1 (en) 2003-10-08 2005-04-21 Bradley T. Messmer Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia
CA2542046A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Fused protein composition
WO2005039549A1 (en) 2003-10-27 2005-05-06 Novartis Ag Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation
JP2007518399A (ja) 2003-12-02 2007-07-12 ジェンザイム コーポレイション 肺癌を診断および治療する組成物並びに方法
WO2005062916A2 (en) 2003-12-22 2005-07-14 Centocor, Inc. Methods for generating multimeric molecules
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
EP1711495A2 (en) 2004-01-23 2006-10-18 Amgen Inc. Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
US8383575B2 (en) 2004-01-30 2013-02-26 Paul Scherrer Institut (DI)barnase-barstar complexes
US20050276756A1 (en) 2004-03-24 2005-12-15 Hoo William S Compositions as adjuvants to improve immune responses to vaccines and methods of use
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
RS55546B1 (sr) 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilonozitol 3-delta kinaze
WO2006083289A2 (en) 2004-06-04 2006-08-10 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
MXPA06014478A (es) 2004-06-11 2007-03-21 Japan Tobacco Inc Derivados de 5-amino-2, 4, 7-trioxo-3, 4, 7, 8-tetrahidro -2h-pirido[2, 3-d]pirimidina y compuestos relacionados para el tratamiento del cancer.
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
ES2427147T3 (es) 2004-06-30 2013-10-29 Mayo Foundation For Medical Education And Research Anticuerpo sHlgM12 útil para tratar esclerosis múltiple
EP1786918A4 (en) 2004-07-17 2009-02-11 Imclone Systems Inc NEW BISPECIFIC ANTIBODY TETRAVALENT
BRPI0513706A (pt) 2004-07-20 2008-05-13 Symphogen As anticorpo policlonal recombinante anti-rhesus d e métodos de produção
WO2006017538A2 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
WO2006021955A2 (en) 2004-08-23 2006-03-02 Mor Research Applications Ltd. Use of bat monoclonal antibody for immunotherapy
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
MX2007003533A (es) * 2004-10-01 2007-05-23 Medarex Inc Metodos de tratar linfomas cd30 positivas.
PL3428191T3 (pl) 2004-10-06 2025-04-07 Mayo Foundation For Medical Education And Research B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
EP1866339B8 (en) 2005-03-25 2021-12-01 GITR, Inc. Gitr binding molecules and uses therefor
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
CA2604032C (en) 2005-04-06 2017-08-22 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
CA2605024C (en) 2005-04-15 2018-05-22 Macrogenics, Inc. Covalent diabodies and uses thereof
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20060263367A1 (en) 2005-05-23 2006-11-23 Fey Georg H Bispecific antibody devoid of Fc region and method of treatment using same
DK1907000T4 (da) 2005-06-08 2020-03-30 The President And Fellows Of Harvard College Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1).
ES2547463T3 (es) 2005-06-17 2015-10-06 Merck Sharp & Dohme Corp. Moléculas de unión a ILT3 y usos de las mismas
JP4557003B2 (ja) 2005-07-01 2010-10-06 株式会社村田製作所 多層セラミック基板およびその製造方法ならびに多層セラミック基板作製用複合グリーンシート
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
SI3248613T1 (sl) 2005-07-18 2022-04-29 Seagen Inc. Konjugati beta-glukuronidni linker-zdravilo
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2520588A1 (en) 2005-08-19 2012-11-07 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
ATE452913T1 (de) 2005-08-26 2010-01-15 Pls Design Gmbh Bivalente igy antikörperkonstrukte für diagnostische und therapeutische anwendungen
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
WO2007044887A2 (en) 2005-10-11 2007-04-19 Transtarget, Inc. Method for producing a population of homogenous tetravalent bispecific antibodies
WO2007056441A2 (en) 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
EP1962961B1 (en) 2005-11-29 2013-01-09 The University Of Sydney Demibodies: dimerisation-activated therapeutic agents
JP2009518320A (ja) 2005-12-05 2009-05-07 シュムフォウエン アクティーゼルスカブ 抗オルトポックスウイルス組換えポリクローナル抗体
DK3184526T3 (en) 2005-12-13 2019-01-14 Incyte Holdings Corp PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR
US20090215084A1 (en) 2006-01-05 2009-08-27 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
US20110212086A1 (en) 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
JP2009526857A (ja) 2006-02-15 2009-07-23 イムクローン・リミテッド・ライアビリティ・カンパニー 機能性抗体
AU2007227292B2 (en) 2006-03-17 2012-04-12 Biogen Ma Inc. Stabilized polypeptide compositions
CA2646965C (en) 2006-03-24 2016-06-21 Jonathan H. Davis Engineered heterodimeric protein domains
US8946391B2 (en) 2006-03-24 2015-02-03 The Regents Of The University Of California Construction of a multivalent scFv through alkyne-azide 1,3-dipolar cycloaddition
CN105177091A (zh) 2006-03-31 2015-12-23 中外制药株式会社 用于纯化双特异性抗体的抗体修饰方法
EP2007423A2 (en) 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
EP2027153B1 (en) 2006-05-25 2014-04-30 Bayer Intellectual Property GmbH Dimeric molecular complexes
US20070274985A1 (en) 2006-05-26 2007-11-29 Stefan Dubel Antibody
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
EP2975057A1 (en) 2006-07-10 2016-01-20 Fujita Health University Novel anti-cd73 antibody
US20090241426A1 (en) 2006-07-14 2009-10-01 Pilkington North America, Inc. Vertical drop vehicle slider assembly
PE20110217A1 (es) 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
WO2008073160A2 (en) 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
WO2008022349A2 (en) 2006-08-18 2008-02-21 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
EA201201533A1 (ru) 2006-08-18 2014-11-28 Новартис Аг Prlr-специфическое антитело и его применения
KR101428116B1 (ko) 2006-08-21 2014-08-07 제넨테크, 인크. 아자-벤조푸라닐 화합물 및 사용 방법
US10118970B2 (en) 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
AU2007342338A1 (en) 2006-09-20 2008-07-17 The Johns Hopkins University Combinatorial therapy of cancer and infectious diseases with anti-B7-H1 antibodies
US20080254512A1 (en) 2006-11-02 2008-10-16 Capon Daniel J Hybrid immunoglobulins with moving parts
US20100061992A1 (en) 2006-11-15 2010-03-11 The Brigham And Women's Hospital, Inc. Therapeutic uses of tim-3 modulators
MX2009005144A (es) 2006-11-22 2009-05-27 Incyte Corp Imidazotriazinas e imidazopirimidinas como inhibidores de cinasa.
JP5391073B2 (ja) 2006-11-27 2014-01-15 ディアデクサス インコーポレーテッド Ｏｖｒ１１０抗体組成物および使用方法
KR101149295B1 (ko) 2006-12-08 2012-07-05 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물
RS53588B1 (sr) 2006-12-08 2015-02-27 Irm Llc Jedinjenja i kompozicije kao inhibitori protein kinaza
US8907065B2 (en) 2006-12-15 2014-12-09 Ablynx N.V. Polypeptides that modulate the interaction between cells of the immune system
CA2947292C (en) 2006-12-27 2019-07-23 Emory University Compositions and methods for the treatment of infections and tumors
ES2667863T3 (es) 2007-03-29 2018-05-14 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US9244059B2 (en) 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
EP2535354B1 (en) 2007-06-18 2017-01-11 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
EP2175884B8 (en) 2007-07-12 2017-02-22 GITR, Inc. Combination therapies employing gitr binding molecules
CA2693707A1 (en) 2007-07-13 2009-03-05 The Johns Hopkins University B7-dc variants
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
ES2628395T3 (es) 2007-08-15 2017-08-02 Bayer Pharma Aktiengesellschaft Anticuerpo regulado por proteasa
EP2195347A1 (en) 2007-08-17 2010-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating and diagnosing hematologic malignancies
US8425897B2 (en) 2007-08-30 2013-04-23 Immutep S.A. Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use
AU2007358569B2 (en) 2007-09-07 2014-09-04 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
AU2008328779B2 (en) 2007-11-27 2014-06-05 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
UY31504A1 (es) 2007-11-30 2009-07-17 Construcciones de union de antigenos
EP2690101B1 (en) 2007-12-19 2015-06-24 Genentech, Inc. 5-Anilinoimidazopyridines and Methods of Use
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
EP3722317B1 (en) 2008-01-15 2024-08-07 The Board of Trustees of the Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
EP2252319A2 (en) 2008-01-29 2010-11-24 The Brigham and Women's Hospital, Inc. Methods for modulating a population of myeloid-derived suppressor cells and uses thereof
CN104548091A (zh) 2008-02-11 2015-04-29 治疗科技公司 用于肿瘤治疗的单克隆抗体
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
AR070924A1 (es) 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
CN102046660A (zh) 2008-03-26 2011-05-04 塞勒兰特治疗公司 骨髓性血液学增殖性病症相关的免疫球蛋白和/或toll样受体蛋白及其用途
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
NZ602791A (en) 2008-05-21 2014-04-30 Incyte Corp Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
BRPI0913031A2 (pt) 2008-05-23 2019-11-26 Novartis Ag derivados de quinolina e quinoxalinas como inibidores de proteína tirosina quinase, seus usos e processo de fabricação, bem como composições farmacêuticas e combinação que os compreende
JP5723769B2 (ja) 2008-06-03 2015-05-27 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
NZ589434A (en) 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY31929A (es) 2008-06-25 2010-01-05 Irm Llc Compuestos y composiciones como inhibidores de cinasa
CA2729810A1 (en) 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc Tgf-.beta. antagonist multi-target binding proteins
WO2010001617A1 (en) 2008-07-04 2010-01-07 Ono Pharmaceutical Co., Ltd. Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US8575427B2 (en) 2008-08-12 2013-11-05 The United States Of America As Represented By The Secretary Of Agriculture Chorismate mutase gene from the potato cyst nematode Globodera rostochiensis
CN102186856B (zh) 2008-08-22 2014-09-24 诺华股份有限公司 作为cdk抑制剂的吡咯并嘧啶化合物
EA023148B1 (ru) 2008-08-25 2016-04-29 Эмплиммьюн, Инк. Композиции на основе антагонистов pd-1 и их применение
US20110159023A1 (en) 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
MX2011002365A (es) 2008-09-02 2011-04-04 Novartis Ag Derivados de picolinamida como inhibidres de cinasa.
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
CA2736816C (en) 2008-09-12 2018-05-22 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
JPWO2010030002A1 (ja) 2008-09-12 2012-02-02 国立大学法人三重大学 外来性ｇｉｔｒリガンド発現細胞
WO2010029435A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
HUE030807T2 (en) 2008-09-26 2017-05-29 Dana Farber Cancer Inst Inc Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
AU2009308707A1 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
WO2010056735A1 (en) 2008-11-11 2010-05-20 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting an oncogenic protein to enhance immunogenicity
PT2370076T (pt) 2008-11-28 2017-03-31 Novartis Ag Combinações de inibidor hsp90
JP5520961B2 (ja) 2008-11-28 2014-06-11 エモリー ユニバーシティ 感染症および腫瘍を処置するための方法
BRPI0922807A2 (pt) 2008-12-04 2015-12-22 Abbott Lab imonuglobulinas de domínio variável duplo e usos dos mesmos
TWI729512B (zh) 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
WO2010084999A1 (en) 2009-01-26 2010-07-29 Protegene, Inc. Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
KR101579771B1 (ko) 2009-03-05 2015-12-28 애브비 인코포레이티드 Ｉｌ-17 결합 단백질
WO2010102278A1 (en) 2009-03-06 2010-09-10 President And Fellows Of Harvard College Methods and compositions for the generation and maintenance of regulatory t cells
JPWO2010110346A1 (ja) 2009-03-24 2012-10-04 独立行政法人理化学研究所 白血病幹細胞マーカー
JP5748653B2 (ja) 2009-04-10 2015-07-15 協和発酵キリン株式会社 抗ｔｉｍ−３抗体を用いた血液腫瘍治療法
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PT2424896E (pt) 2009-04-30 2015-11-30 Univ Ramot Anticorpos anti-ceacam1 e métodos de utilização dos mesmos
MX2011011670A (es) 2009-05-01 2011-11-18 Abbott Lab Inmunoglobulinas de dominio variable dual y usos de las mismas.
PE20120813A1 (es) 2009-05-01 2012-08-09 Abbott Lab Inmunoglobulina con dominio variable dual
US20120141501A1 (en) 2009-05-29 2012-06-07 Forerunner Pharma Research Co. Ltd Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component
CN102802661B (zh) 2009-06-22 2016-01-13 米迪缪尼有限公司 用于位点特异性偶联的工程改造的Fc区
WO2010149755A1 (en) 2009-06-26 2010-12-29 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
EP2456790A1 (en) 2009-07-20 2012-05-30 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
UY32808A (es) 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
SG178602A1 (en) 2009-09-01 2012-04-27 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN102574924A (zh) 2009-09-03 2012-07-11 先灵公司 抗-gitr抗体
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
JP6091894B2 (ja) 2009-09-16 2017-03-15 ジェネンテック， インコーポレイテッド コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用
EP2482849B1 (en) 2009-09-30 2018-06-06 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
BR112012008833A2 (pt) 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
CN104961829B (zh) 2009-11-24 2018-08-21 米迪缪尼有限公司 针对b7-h1的靶向结合剂
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
CN102770456B (zh) 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
SI2519543T1 (sl) 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
CA2790134A1 (en) 2010-02-16 2011-08-25 Valorisation-Recherche, Limited Partnership Pd-1 modulation and uses thereof for modulating hiv replication
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
JP6066732B2 (ja) 2010-03-05 2017-01-25 ザ・ジョンズ・ホプキンス・ユニバーシティー 標的免疫調節抗体および融合タンパク質に基づく組成物および方法
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CN102892786B (zh) 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
WO2011131472A1 (en) 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
US20110280877A1 (en) 2010-05-11 2011-11-17 Koji Tamada Inhibition of B7-H1/CD80 interaction and uses thereof
PL2571532T3 (pl) 2010-05-14 2017-10-31 Abbvie Inc Białka wiążące IL-1
CN103079644B (zh) 2010-06-11 2017-02-15 协和发酵麒麟株式会社 抗tim‑3抗体
JP2013532153A (ja) 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012018538A2 (en) 2010-07-26 2012-02-09 Schering Corporation Bioassays for determining pd-1 modulation
SG188190A1 (en) 2010-08-03 2013-04-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
PH12013500333A1 (en) 2010-08-20 2013-04-22 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
WO2012054438A1 (en) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
WO2012061374A2 (en) 2010-11-02 2012-05-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
UY33707A (es) 2010-11-04 2012-05-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
JP6014596B2 (ja) 2010-11-09 2016-10-25 メディミューン，エルエルシー 均一コンジュゲーションのための抗体足場
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2654792A4 (en) 2010-12-22 2016-05-11 Abbvie Inc HALF IMMUNOGLOBULIN BINDING PROTEINS AND USES THEREOF
US20120195900A1 (en) 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
US8814630B2 (en) 2011-01-04 2014-08-26 Carl T. Rittberger PVC beehive
CN103649117B (zh) 2011-02-04 2016-09-14 霍夫曼-拉罗奇有限公司 Fc变体及其生成方法
KR102031020B1 (ko) 2011-03-31 2019-10-14 머크 샤프 앤드 돔 코포레이션 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
US20140234320A1 (en) 2011-06-20 2014-08-21 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
CN103796680A (zh) 2011-06-21 2014-05-14 约翰霍普金斯大学 用于增强针对赘生物的基于免疫的治疗的聚焦放射
BR112013033661A2 (pt) 2011-06-30 2017-01-24 Genzyme Corp inibidores de ativação de células t
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
BR122022000334B1 (pt) 2011-08-01 2023-03-21 Genentech, Inc Composição farmacêutica compreendendo um antagonista de ligação ao eixo pd-1 e um inibidor de mek
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
WO2013043647A1 (en) 2011-09-19 2013-03-28 The Johns Hopkins University Cancer immunotherapy
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
SI2771364T1 (sl) 2011-10-27 2019-10-30 Genmab As Produkcija heterodimernih proteinov
KR102038310B1 (ko) * 2011-11-16 2019-11-01 베링거 인겔하임 인터내셔날 게엠베하 항 ｉｌ-36ｒ 항체
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
GB201120527D0 (en) 2011-11-29 2012-01-11 Ucl Business Plc Method
JP6385277B2 (ja) 2011-12-01 2018-09-05 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 癌治療のための抗ｃｅａｃａｍ１組換え型抗体
CN102492038B (zh) 2011-12-09 2014-05-28 中国人民解放军军事医学科学院基础医学研究所 抗人Tim-3的中和性单克隆抗体L3D及其用途
JO3357B1 (ar) 2012-01-26 2019-03-13 Novartis Ag مركبات إيميدازوبيروليدينون
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
BR112014027181A2 (pt) 2012-05-15 2017-06-27 Novartis Ag derivados de benzamida para a inibição da atividade de abl1, abl2 e bcr-abl1
PL2861579T3 (pl) 2012-05-15 2018-07-31 Novartis Ag Pochodne benzamidu do hamowania aktywności ABL 1, ABL 2 i BCR-ABL 1
ES2665539T3 (es) 2012-05-15 2018-04-26 Novartis Ag Derivados de benzamida para inhibir la actividad de ABL1, ABL2 y BCR-ABL1
KR102702287B1 (ko) 2012-05-15 2024-09-04 브리스톨-마이어스 스큅 컴퍼니 Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법
CA2870339C (en) 2012-05-15 2020-06-02 Novartis Ag Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1
KR102410078B1 (ko) 2012-05-31 2022-06-22 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
EP2855528B1 (en) 2012-05-31 2019-06-19 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
HK1205198A1 (en) 2012-07-27 2015-12-11 Novartis Ag Prediction of treatment response to jak/stat inhibitor
US20150190505A1 (en) 2012-07-30 2015-07-09 Alex Wah Hin Yeung Live and in-vivo tumor specific cancer vaccine system developed by co-administration of either at least two or all three of the following components such as tumor cells, an oncolytic virus vector with transgenic expression of gm-csf and an immune checkpoint modulator
WO2014022332A1 (en) 2012-07-31 2014-02-06 The Brigham And Women's Hospital, Inc. Modulation of the immune response
EP2890715B1 (en) 2012-08-03 2020-12-16 Dana-Farber Cancer Institute, Inc. Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use
WO2014028502A1 (en) * 2012-08-13 2014-02-20 ImmunGene Inc. Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
US20150250837A1 (en) 2012-09-20 2015-09-10 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
AU2013327116C1 (en) 2012-10-02 2018-08-30 Bristol-Myers Squibb Company Combination of anti-KIR antibodies and anti-PD-1 antibodies to treat cancer
WO2014055897A2 (en) 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
CA2890663A1 (en) 2012-11-08 2014-05-15 Novartis Ag Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
EP2925365A1 (en) 2012-11-28 2015-10-07 Novartis AG Combination therapy
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
WO2014165082A2 (en) 2013-03-13 2014-10-09 Medimmune, Llc Antibodies and methods of detection
PE20151939A1 (es) 2013-03-14 2016-01-08 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
MY210104A (en) 2013-03-15 2025-08-27 Glaxosmithkline Ip Dev Ltd Anti-lag-3 binding proteins
EP2981821B2 (en) 2013-04-02 2021-11-03 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
PT2992017T (pt) 2013-05-02 2021-01-29 Anaptysbio Inc Anticorpos dirigidos contra a morte programada 1 (pd-1)
SI2996473T1 (sl) 2013-05-18 2019-12-31 Aduro Biotech, Inc. Sestavki in postopki za aktiviranje signaliziranja, odvisnega od "stimulator interferonskih genov"
CN103242448B (zh) 2013-05-27 2015-01-14 郑州大学 一种全人源化抗pd-1单克隆抗体及其制备方法和应用
KR20160013049A (ko) 2013-06-03 2016-02-03 노파르티스 아게 항-pd-l1 항체 및 mek 억제제 및/또는 braf 억제제의 조합물
RU2702108C2 (ru) 2013-07-16 2019-10-04 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающих с осью pd-1, и ингибиторов tigit
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
ES2827679T3 (es) 2013-08-20 2021-05-24 Merck Sharp & Dohme Tratamiento del cáncer con una combinación de un antagonista de PD-1 y dinaciclib
US10077305B2 (en) 2013-09-10 2018-09-18 Medimmune Limited Antibodies against PD-1 and uses thereof
KR20210143932A (ko) 2013-09-11 2021-11-29 메디뮨 리미티드 종양 치료용 항-ｂ7-ｈ1 항체
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
RS63571B9 (sr) 2013-09-13 2023-02-28 Beigene Switzerland Gmbh Anti-pd1 antitela i njihova primena kao terapeutska i dijagnostička sredstva
EP3508502B1 (en) 2013-09-20 2023-04-26 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
LT3049441T (lt) 2013-09-27 2020-02-10 F. Hoffmann-La Roche Ag Anti-pdl1 antikūnų kompozicija
AU2014339900B2 (en) 2013-10-25 2019-10-24 Dana-Farber Cancer Institute, Inc. Anti-PD-L1 monoclonal antibodies and fragments thereof
CN105848674A (zh) 2013-11-11 2016-08-10 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
WO2015081158A1 (en) 2013-11-26 2015-06-04 Bristol-Myers Squibb Company Method of treating hiv by disrupting pd-1/pd-l1 signaling
US20160303231A1 (en) 2013-12-11 2016-10-20 Robert Iannone Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
PL3081576T3 (pl) 2013-12-12 2020-03-31 Shanghai Hengrui Pharmaceutical Co., Ltd. Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
AU2014364606A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
CA2935375C (en) 2014-01-06 2023-08-08 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
HUE057917T2 (hu) 2014-01-15 2022-06-28 Kadmon Corp Llc Immunmodulátor szerek
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
PT3556775T (pt) 2014-01-28 2021-12-31 Bristol Myers Squibb Co Anticorpos anti-lag-3 para tratar neoplasias malignas hematológicas
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
JP2017508785A (ja) 2014-02-04 2017-03-30 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ 癌を治療するためのｐｄ−１アンタゴニストおよびｉｄｏ１阻害剤の組み合わせ
CN105979961B (zh) 2014-02-05 2020-12-18 西达-赛奈医疗中心 用于治疗癌症和感染性疾病的方法和组合物
SI3105246T1 (sl) 2014-02-10 2021-11-30 Merck Patent Gmbh Ciljana inhibicija TGF BETA
KR20220127940A (ko) 2014-03-05 2022-09-20 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료
EP3660050A1 (en) * 2014-03-14 2020-06-03 Novartis AG Antibody molecules to lag-3 and uses thereof
CN115590953A (zh) 2014-05-15 2023-01-13 百时美施贵宝公司（Us） 使用抗pd-1抗体和另一种抗癌剂的组合治疗肺癌
EP3149042B1 (en) 2014-05-29 2019-08-28 Spring Bioscience Corporation Pd-l1 antibodies and uses thereof
WO2015195163A1 (en) 2014-06-20 2015-12-23 R-Pharm Overseas, Inc. Pd-l1 antagonist fully human antibody
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
US10544225B2 (en) 2014-07-03 2020-01-28 Beigene, Ltd. Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
AU2015305531B2 (en) 2014-08-19 2021-05-20 Novartis Ag Anti-CD123 chimeric antigen receptor (CAR) for use in cancer treatment
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
US20170209574A1 (en) 2014-10-03 2017-07-27 Novartis Ag Combination therapies
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
LT3212670T (lt) 2014-10-29 2021-02-10 Five Prime Therapeutics, Inc. Kombinuotasis vėžio gydymas
US20170320954A1 (en) 2014-11-17 2017-11-09 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
IL283006B2 (en) 2015-04-01 2023-10-01 Anaptysbio Inc Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
HRP20220893T1 (hr) * 2015-04-08 2022-10-14 Novartis Ag Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor
BR112018000768A2 (pt) 2015-07-13 2018-09-25 Cytomx Therapeutics Inc anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
US11001628B2 (en) 2015-07-29 2021-05-11 Novartis Ag Combined use of anti PD-1 and anti M-CSF antibodies in the treatment of cancer
PL3317301T3 (pl) 2015-07-29 2021-11-15 Novartis Ag Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
EP3328407A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination of pd-1 antagonist with an egfr inhibitor
SI3334431T1 (sl) 2015-08-11 2020-01-31 Novartis Ag 5-bromo-2,6-di-(1h-pirazol-l-il)pyrimidin-4-amin za uporabo v zdravljenju raka
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
AU2016343993A1 (en) * 2015-10-28 2018-05-10 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
ES2823279T3 (es) 2015-12-07 2021-05-06 Merck Patent Gmbh Formulación farmacéutica acuosa que comprende el anticuerpo anti-PD-1 Avelumab
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
US11413340B2 (en) * 2015-12-22 2022-08-16 Novartis Ag Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
WO2017122130A1 (en) * 2016-01-11 2017-07-20 Novartis Ag Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
EP3448428A4 (en) 2016-04-25 2019-11-27 Medimmune, LLC COMPOSITIONS WITH CO FORMULATION OF ANTI-PD-L1 AND ANTI-CTLA-4 ANTIBODIES
US9567399B1 (en) * 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3507367A4 (en) * 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
SG11201900677SA (en) * 2016-07-28 2019-02-27 Novartis Ag Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
AU2018277824A1 (en) 2017-05-30 2019-10-17 Bristol-Myers Squibb Company Treatment of LAG-3 positive tumors
EP3635410A4 (en) 2017-06-04 2021-03-10 Rappaport Family Institute for Research in the Medical Sciences PROCEDURE FOR PREDICTING PERSONALIZED RESPONSE TO CANCER TREATMENT USING IMMUNE CHECKPOINT INHIBITORS AND KITS
KR20200021087A (ko) * 2017-06-22 2020-02-27 노파르티스 아게 Cd73에 대한 항체 분자 및 이의 용도
JP2020525483A (ja) 2017-06-27 2020-08-27 ノバルティス アーゲー 抗ｔｉｍ−３抗体のための投与レジメンおよびその使用
CN111163798A (zh) 2017-07-20 2020-05-15 诺华股份有限公司 用于抗lag-3抗体的给药方案及其用途
WO2019018640A1 (en) 2017-07-21 2019-01-24 Novartis Ag POSOLOGICAL REGIMES FOR ANTI-GITREN ANTIBODIES AND USES THEREOF
RU2020119578A (ru) * 2017-11-16 2021-12-17 Новартис Аг Комбинированные терапии
CN109970856B (zh) * 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
CN113227137A (zh) 2018-12-21 2021-08-06 诺华股份有限公司 IL-1β抗体在骨髓增生异常综合征的治疗或预防中的用途
WO2021053490A1 (en) 2019-09-16 2021-03-25 Novartis Ag Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosis
TW202128191A (zh) 2019-10-21 2021-08-01 瑞士商諾華公司 Tim-3抑制劑及其用途
MX2022004766A (es) 2019-10-21 2022-05-16 Novartis Ag Terapias combinadas con venetoclax e inhibidores de tim-3.
TW202135859A (zh) 2019-12-20 2021-10-01 瑞士商諾華公司 組合療法
BR112022012310A2 (pt) 2020-01-17 2022-09-06 Novartis Ag Combinação compreendendo um inibidor de tim-3 e um agente hipometilante para uso no tratamento de síndrome mielodisplásica ou leucemia mielomonocítica crônica
WO2022195551A1 (en) 2021-03-18 2022-09-22 Novartis Ag Biomarkers for cancer and methods of use thereof

Also Published As

Publication number Publication date
TW202033561A (zh) 2020-09-16
DK3116909T3 (da) 2020-01-20
US20150259420A1 (en) 2015-09-17
NZ722091A (en) 2024-04-26
WO2015138920A1 (en) 2015-09-17
CL2016002112A1 (es) 2017-06-09
EP3116909A1 (en) 2017-01-18
MY187246A (en) 2021-09-14
TWI898718B (zh) 2025-09-21
KR20160134668A (ko) 2016-11-23
US20170210804A1 (en) 2017-07-27
BR112016018408A2 (pt) 2017-12-26
CL2018002694A1 (es) 2018-11-23
KR20220126813A (ko) 2022-09-16
TWI852057B (zh) 2024-08-11
UY36032A (es) 2015-10-30
AU2015229103B2 (en) 2020-07-23
CN106103484A (zh) 2016-11-09
IL288012A (en) 2022-01-01
HUE048531T2 (hu) 2020-07-28
IL272488B (en) 2021-12-01
TW202517678A (zh) 2025-05-01
US20210009687A1 (en) 2021-01-14
RS59853B1 (sr) 2020-02-28
SI3116909T1 (sl) 2020-03-31
TWI697500B (zh) 2020-07-01
JP7030750B2 (ja) 2022-03-07
ME03558B (me) 2020-07-20
HRP20192346T1 (hr) 2020-03-20
TW201540727A (zh) 2015-11-01
JP2020005645A (ja) 2020-01-16
CR20160425A (es) 2017-05-26
IL246781B (en) 2020-03-31
AU2015229103A1 (en) 2016-08-04
KR102442436B1 (ko) 2022-09-15
MX2022001043A (es) 2022-02-10
JOP20150048B1 (ar) 2021-08-17
MX2016011993A (es) 2016-12-09
PH12016501545A1 (en) 2016-09-14
US9908936B2 (en) 2018-03-06
CU24481B1 (es) 2020-03-04
BR122024001145A2 (pt) 2024-02-27
AU2020256466A1 (en) 2020-11-12
PE20170071A1 (es) 2017-03-17
US20250382365A1 (en) 2025-12-18
EP3116909B1 (en) 2019-11-13
AU2015229103C1 (en) 2020-10-22
US12252535B2 (en) 2025-03-18
ECSP16081503A (es) 2018-09-30
CA2936962C (en) 2024-03-05
PT3116909T (pt) 2020-01-30
TWI777174B (zh) 2022-09-11
CN106103484B (zh) 2021-08-20
IL246781A0 (en) 2016-08-31
EP3660050A1 (en) 2020-06-03
LT3116909T (lt) 2020-02-10
PH12016501545B1 (en) 2023-12-06
KR20240110004A (ko) 2024-07-12
GT201600185A (es) 2018-11-27
AU2024204473A1 (en) 2024-08-15
SG11201605951YA (en) 2016-10-28
JP2022084616A (ja) 2022-06-07
TW202321306A (zh) 2023-06-01
IL272488A (en) 2020-03-31
PL3116909T3 (pl) 2020-05-18
AU2015229103C9 (en) 2020-11-26
JP2017516489A (ja) 2017-06-22
JP6576962B2 (ja) 2019-09-18
US20180086830A1 (en) 2018-03-29
ZA201604740B (en) 2022-12-21
US10711060B2 (en) 2020-07-14
CN113583129A (zh) 2021-11-02
CA2936962A1 (en) 2015-09-17
JP2024063093A (ja) 2024-05-10
ES2770684T3 (es) 2020-07-02
MX389741B (es) 2025-03-20
CY1122510T1 (el) 2021-01-27
AU2020256466B2 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
EA201691765A1 (ru) Молекулы антител против lag-3 и их применения
EA201691556A1 (ru) Молекулы антител к tim-3 и их применение
EA201691488A1 (ru) Молекулы антител против pd-1 и их применения
EA201790834A1 (ru) Молекулы антител к pd-l1 и их применение
PH12018501206A1 (en) Antibody molecules to pd-1 and uses thereof
EA202091540A1 (ru) Антитела к lilrb2
EA202090104A1 (ru) Молекулы антител к cd73 и пути их применения
ZA201803366B (en) Antibody molecules to april and uses thereof